10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by Nikko Asset Management Americas Inc.

Nikko Asset Management Americas Inc. decreased its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 10.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,713,484 shares of the company's stock after selling 659,728 shares during the quarter. Nikko Asset Management Americas Inc. owned approximately 4.72% of 10x Genomics worth $82,046,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. KBC Group NV lifted its position in shares of 10x Genomics by 38.8% during the 3rd quarter. KBC Group NV now owns 3,225 shares of the company's stock worth $73,000 after buying an additional 902 shares during the last quarter. Atria Wealth Solutions Inc. raised its stake in 10x Genomics by 9.6% during the 4th quarter. Atria Wealth Solutions Inc. now owns 10,788 shares of the company's stock worth $155,000 after acquiring an additional 943 shares in the last quarter. First Horizon Advisors Inc. lifted its position in 10x Genomics by 53.3% in the third quarter. First Horizon Advisors Inc. now owns 2,910 shares of the company's stock valued at $66,000 after acquiring an additional 1,012 shares during the last quarter. Blue Trust Inc. boosted its stake in 10x Genomics by 73.1% in the fourth quarter. Blue Trust Inc. now owns 3,075 shares of the company's stock valued at $44,000 after acquiring an additional 1,299 shares in the last quarter. Finally, Sound Income Strategies LLC grew its holdings in shares of 10x Genomics by 65.2% during the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company's stock worth $48,000 after purchasing an additional 1,330 shares during the last quarter. 84.68% of the stock is owned by institutional investors and hedge funds.

Remove Ads

10x Genomics Stock Up 4.4 %

Shares of NASDAQ TXG traded up $0.44 during midday trading on Friday, hitting $10.39. The company had a trading volume of 3,433,644 shares, compared to its average volume of 2,001,467. The business has a 50-day simple moving average of $12.79 and a two-hundred day simple moving average of $15.67. 10x Genomics, Inc. has a twelve month low of $9.27 and a twelve month high of $39.30. The firm has a market capitalization of $1.27 billion, a price-to-earnings ratio of -6.84 and a beta of 1.93.

10x Genomics (NASDAQ:TXG - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. On average, equities analysts forecast that 10x Genomics, Inc. will post -1.43 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. JPMorgan Chase & Co. decreased their target price on 10x Genomics from $14.00 to $12.00 and set a "neutral" rating for the company in a research report on Thursday, February 13th. Stifel Nicolaus decreased their price target on shares of 10x Genomics from $21.00 to $18.00 and set a "buy" rating for the company in a research note on Thursday, February 13th. Leerink Partners lowered shares of 10x Genomics from an "outperform" rating to a "market perform" rating and dropped their price objective for the company from $25.00 to $12.00 in a research note on Thursday, February 13th. Weiss Ratings reiterated a "sell (e+)" rating on shares of 10x Genomics in a research note on Friday, March 7th. Finally, Barclays dropped their price target on 10x Genomics from $19.00 to $18.00 and set an "overweight" rating on the stock in a research report on Monday, February 10th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $20.21.

Insider Buying and Selling

In other 10x Genomics news, CEO Serge Saxonov sold 5,092 shares of the company's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $11.07, for a total value of $56,368.44. Following the sale, the chief executive officer now owns 879,482 shares of the company's stock, valued at $9,735,865.74. This represents a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Alan Mateo acquired 40,000 shares of the company's stock in a transaction dated Friday, February 21st. The shares were acquired at an average cost of $11.14 per share, with a total value of $445,600.00. Following the completion of the purchase, the director now owns 61,691 shares in the company, valued at approximately $687,237.74. This represents a 184.41 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 10.03% of the stock is currently owned by insiders.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.